Cagrilintide Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

Cagrilintide is an investigational weight-loss drug that mimics amylin, a hormone your pancreas releases with insulin to signal fullness. Given as a once-weekly injection, it reduces appetite through a different pathway than GLP-1 drugs, which is why it gets paired with semaglutide in the combination called CagriSema. As of 2026, cagrilintide is still in development and not yet FDA approved.

This guide covers what cagrilintide is, how it works, what the trials show alone and combined with semaglutide, its dosing, side effects, and regulatory status. Cagrilintide is one of the more genuinely promising compounds in the obesity pipeline, with strong phase 3 data behind the combination product. The honest caveat is that it is not yet available as an approved medication, and much of the buzz online involves research-grade material sold outside legitimate channels.

At TrimRx, we believe understanding your options clearly is the first step toward a health plan that fits. If you are exploring weight-management approaches, our free assessment quiz is a good place to start.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Cagrilintide?

Cagrilintide is a long-acting analog of amylin, a hormone co-released with insulin by the pancreas after eating. Amylin helps signal fullness, slow stomach emptying, and reduce food intake. Cagrilintide is engineered to do the same job but last about a week per dose.

Quick Answer: Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk for weight management, given as a once-weekly injection.

Natural amylin breaks down quickly, so it cannot be used as a weekly medication on its own. Cagrilintide is acylated, meaning a fatty-acid chain is attached that lets it bind to albumin in the blood and stay active far longer. This is the same chemistry trick used to make semaglutide long-acting.

Novo Nordisk, the company behind semaglutide and tirzepatide’s competitor products, is developing cagrilintide both as a standalone agent and, more prominently, combined with semaglutide as CagriSema. The combination is where most of the late-stage trial data lives, because pairing two appetite pathways produces larger weight loss than either alone.

How Does Cagrilintide Work?

Cagrilintide works by activating amylin receptors in the brain, particularly in the hindbrain area called the area postrema, which reduces appetite and food intake. This is a distinct mechanism from GLP-1 drugs, which is why the two combine well.

Amylin and GLP-1 are different fullness signals. GLP-1 medications like semaglutide act mainly on GLP-1 receptors. Cagrilintide acts on amylin receptors. Because they hit separate pathways, combining them adds their appetite-suppressing effects rather than overlapping, producing more weight loss than maxing out either alone.

Research published in 2025 confirmed that cagrilintide lowers body weight through brain amylin receptors, specifically amylin receptors 1 and 3. The practical result is reduced hunger and earlier fullness, so people eat less without the constant willpower battle. It is the same general outcome as GLP-1 therapy, reached through a different door.

What Weight Loss Does Cagrilintide Produce?

On its own, cagrilintide produced up to about 10.8% weight loss over 26 weeks in its phase 2 trial. Combined with semaglutide as CagriSema, it reached 22.7% over 68 weeks in phase 3, among the strongest results in the obesity field.

The phase 2 monotherapy trial (Lau et al., 2021, published in the Lancet) tested five cagrilintide doses from 0.3 mg to 4.5 mg weekly in 706 people across 10 countries. Weight loss ranged from 6.0% at the lowest dose to 10.8% at the highest, beating both placebo and the comparator liraglutide.

The combination data is more striking. In REDEFINE 1, published in the New England Journal of Medicine in 2025, CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced 22.7% weight loss at week 68, versus 16.1% for semaglutide alone and 11.8% for cagrilintide alone. Sixty percent of participants lost at least 20% of their body weight. That places CagriSema near the top of weight-loss results seen with any obesity therapy.

How Does Cagrilintide Compare to Semaglutide?

Cagrilintide and semaglutide work through different hormone pathways, and the headline finding is that combining them beats either one alone. Semaglutide is FDA approved and available now; cagrilintide is not yet approved.

In the REDEFINE 1 trial, semaglutide alone produced 16.1% weight loss, cagrilintide alone produced 11.8%, and the two together produced 22.7%. The combination clearly outperformed each component. This is the central reason cagrilintide is being developed mainly as half of CagriSema rather than as a standalone drug.

The practical difference today is availability. Semaglutide, the molecule in Ozempic® and Wegovy®, is an approved, prescribable medication. Cagrilintide is investigational. So while the science points to cagrilintide as a strong complement to semaglutide, it is not something a patient can legitimately obtain as an approved therapy yet. That gap is the most important thing to understand about it in 2026.

How Is Cagrilintide Dosed?

Cagrilintide is dosed as a once-weekly subcutaneous injection with gradual dose escalation, typically starting low and stepping up over weeks to a target around 2.4 mg in the combination or higher in monotherapy studies. The slow ramp is essential to limit nausea.

In the phase 2 monotherapy trial, doses tested ran from 0.3 mg up to 4.5 mg weekly. In the CagriSema combination studied in phase 3, the target was cagrilintide 2.4 mg paired with semaglutide 2.4 mg. Escalation usually moves up in steps, often starting near 0.25 mg and increasing every few weeks, mirroring how GLP-1 drugs are titrated.

Because cagrilintide is not FDA approved, there is no official patient dosing label. The numbers come from clinical trials, not from an approved prescribing guide. Any dosing seen on research-chemical sites is not a substitute for a validated medical protocol, and self-dosing investigational peptides carries real risk without medical oversight.

What Are the Side Effects of Cagrilintide?

The most common side effects of cagrilintide are gastrointestinal, especially nausea, vomiting, and reduced appetite, similar to GLP-1 drugs. These are usually mild to moderate and managed with gradual dose escalation.

Because cagrilintide slows stomach emptying and reduces appetite, the digestive system bears most of the side-effect burden. In the trials, nausea was the most frequently reported issue, particularly during dose escalation, and tended to ease as people adjusted. The combination with semaglutide in CagriSema showed a side-effect profile broadly in line with what you would expect from stacking two appetite-suppressing mechanisms.

Most adverse events in the trials were mild to moderate, and the gradual titration approach is specifically designed to reduce them. Longer-term and rarer effects will become clearer as the regulatory review and post-market data accumulate. As an investigational drug, cagrilintide’s full safety picture is still being established, which is part of why approval and monitoring matter.

Is Cagrilintide FDA Approved?

No, cagrilintide is not FDA approved as of 2026. It remains an investigational drug in late-stage development. Novo Nordisk was expected to file CagriSema with the FDA around early 2026, with approval anticipated later in 2026 or into 2027.

This is the most important compliance point. Cagrilintide cannot be legitimately prescribed as an approved weight-loss medication yet. The phase 3 REDEFINE program produced strong data, which supports the filing, but a strong trial is not the same as an available, approved therapy.

What this means practically is that cagrilintide sold online as a “research peptide” is not an approved medical product. Buying and self-administering unapproved injectables carries real risks around purity, dosing, and safety, with no medical oversight. Anyone interested in cagrilintide should watch the regulatory timeline rather than seeking it through unregulated channels.

Who Is Cagrilintide Being Developed For?

Cagrilintide is being developed for adults with overweight or obesity, and the phase 3 program also studied it in people with type 2 diabetes. The target population mirrors that of approved GLP-1 weight-loss drugs.

The REDEFINE 1 trial enrolled adults with overweight or obesity, while REDEFINE 2 studied CagriSema in adults with type 2 diabetes and overweight or obesity, showing 15.7% weight loss versus 3.1% with placebo at week 68. So the development program covers both the general obesity population and those with diabetes.

If approved, cagrilintide as part of CagriSema would slot in as another option for people seeking significant weight loss, particularly those who want the larger effect of a dual-mechanism therapy. Until then, the existing approved options, including semaglutide and tirzepatide, remain the available choices for patients now.

Key Takeaway: Combined with semaglutide as CagriSema, it produced 22.7% weight loss in the REDEFINE 1 phase 3 trial (NEJM, 2025).

How Does Cagrilintide Fit the Obesity Drug Landscape?

Cagrilintide represents the next wave of obesity drugs that combine multiple appetite pathways for larger weight loss. It joins tirzepatide, which combines GLP-1 and GIP activity, in moving beyond single-hormone approaches.

The field has shifted from single-target drugs toward combinations. Semaglutide targets GLP-1. Tirzepatide targets GLP-1 and GIP. CagriSema targets GLP-1 and amylin. Each step toward hitting multiple pathways has tended to produce larger average weight loss, and CagriSema’s 22.7% result reflects that trend.

For patients, this means the menu of effective options is expanding, with cagrilintide-based therapy likely joining it once approved. The practical takeaway is to focus on what is available and proven now while keeping an eye on the pipeline. Cagrilintide is a strong candidate, but candidates are not yet treatments.

What Did the REDEFINE 2 Trial Show?

REDEFINE 2 tested CagriSema in adults with type 2 diabetes and overweight or obesity, and it produced 15.7% weight loss at week 68 versus 3.1% with placebo. This extended the strong phase 3 results into the diabetes population.

The trial enrolled about 1,200 adults across multiple sites and ran for 68 weeks, the same duration as REDEFINE 1. People with type 2 diabetes typically lose less weight on these medications than those without diabetes, so the 15.7% figure, while lower than REDEFINE 1’s 22.7%, is consistent with that pattern and still represents substantial weight loss for this group.

Novo Nordisk also reported meaningful improvements in blood sugar control, with a reported HbA1c reduction of around 1.91%, indicating the combination helps glycemic management alongside weight. Together, REDEFINE 1 and REDEFINE 2 build the case that CagriSema works across both the general obesity population and people with type 2 diabetes, which strengthens the regulatory filing.

Why Combine Amylin and GLP-1?

Combining amylin and GLP-1 pathways works because they are separate fullness signals, so hitting both produces more appetite suppression than maxing out either alone. This is the scientific rationale behind CagriSema.

Your body uses multiple overlapping signals to regulate hunger and fullness. GLP-1 and amylin are two of them, released after eating and acting partly on different brain regions. A drug that activates only one pathway leaves the other untouched. By engaging both, CagriSema recruits more of the body’s natural satiety machinery at once.

The trial results bear this out: 22.7% combined versus 16.1% and 11.8% for the single agents. The combination is not simply additive in a perfect arithmetic sense, but it clearly beats either component. This multi-pathway logic is the same reason tirzepatide, which hits GLP-1 and GIP, outperforms single-target GLP-1 drugs. The obesity field has learned that more pathways generally means more weight loss.

How Does Cagrilintide Compare to Tirzepatide?

Cagrilintide and tirzepatide both represent dual-pathway approaches, but they target different second hormones, and tirzepatide is already FDA approved while cagrilintide is not. The comparison is between two leading multi-mechanism strategies.

Tirzepatide, the molecule in Mounjaro® and Zepbound®, activates GLP-1 and GIP receptors. CagriSema activates GLP-1 and amylin receptors. Both produce large weight loss. In SURMOUNT-1 (Jastreboff 2022, NEJM), tirzepatide produced weight loss in a similar high range to what CagriSema showed in REDEFINE 1, though the trials differ enough that direct comparison is imperfect.

The decisive practical difference is availability. Tirzepatide is approved and prescribable now. CagriSema is still in regulatory review. So while cagrilintide-based therapy looks competitive with tirzepatide on the science, only one of them is an option for patients today. For someone seeking treatment now, that distinction matters more than small differences in trial percentages.

What Is the Cagrilintide Development Timeline?

Cagrilintide’s development moved from early phase 1 work to strong phase 3 results over several years, with regulatory filing expected around early 2026. The pace reflects how much priority obesity drugs now get.

The phase 1b combination study (Enebo et al., 2021, Lancet) established that cagrilintide and semaglutide could be given together safely. The phase 2 monotherapy trial (Lau et al., 2021, Lancet) showed cagrilintide alone produced meaningful weight loss. The phase 3 REDEFINE program then tested the combination at scale, with REDEFINE 1 reported in late 2024 and published in NEJM in 2025, and REDEFINE 2 reporting in early 2025.

Based on that data, Novo Nordisk was expected to submit CagriSema to the FDA around the first quarter of 2026, with approval anticipated later in 2026 or into 2027. Timelines can shift, and approval is never guaranteed until it happens. The takeaway is that cagrilintide is far along but not across the finish line, so patients should treat it as a near-future possibility rather than a current option.

Should You Wait for Cagrilintide or Start Now?

For most people seeking weight loss today, the better move is to start with an available, approved option rather than wait for cagrilintide, which is not yet on the market. Effective treatments already exist.

Waiting for an investigational drug means waiting through regulatory review, potential delays, and an uncertain launch timeline, all while carrying the health effects of excess weight in the meantime. Meanwhile, approved options like semaglutide and tirzepatide produce substantial weight loss and are accessible now, including through compounded formulations from 503A pharmacies with personalization.

If cagrilintide-based therapy is approved and turns out to fit your needs better, switching or adding it later is a conversation you can have with your provider then. The general principle in obesity care is that the best time to start an effective, available treatment is usually now, not at some future date contingent on a drug that has not yet cleared approval. Starting now does not lock you out of future options.

Path Forward with TrimRx

Cagrilintide is one of the more promising compounds in the obesity pipeline, with strong phase 3 data behind the CagriSema combination. The honest reality in 2026 is that it is not yet FDA approved, so it is not an option patients can legitimately access as an approved therapy right now.

At TrimRX, our weight-management programs are built on options that are available and clinically supported, like compounded semaglutide and tirzepatide, and we are expanding into peptide and wellness offerings with honest evidence framing. We track the pipeline closely and will tell you plainly what is proven, what is available, and what is still in trials.

If you want to find an effective, available option that fits your goals today, our free assessment quiz takes a few minutes and connects you with a licensed provider who can review your history and lay out realistic choices.

Bottom line: The main side effects are gastrointestinal, especially nausea, managed with gradual dose escalation.

FAQ

Is Cagrilintide Approved by the FDA?

No. As of 2026, cagrilintide is investigational and not FDA approved. Novo Nordisk was expected to file CagriSema around early 2026, with approval anticipated later. It cannot be legitimately prescribed as an approved weight-loss medication yet.

How Much Weight Loss Does Cagrilintide Cause?

Alone, cagrilintide produced up to about 10.8% weight loss over 26 weeks in phase 2. Combined with semaglutide as CagriSema, it reached 22.7% over 68 weeks in the REDEFINE 1 phase 3 trial, among the strongest results in the field.

What Is the Difference Between Cagrilintide and CagriSema?

Cagrilintide is the amylin analog on its own. CagriSema is the fixed-dose combination of cagrilintide and semaglutide. The combination produces larger weight loss than either component alone, which is why it is the main product in development.

How Does Cagrilintide Work Compared to Semaglutide?

Cagrilintide activates amylin receptors in the brain to reduce appetite, while semaglutide acts on GLP-1 receptors. Because they use different pathways, combining them adds their effects, producing more weight loss than either achieves alone.

What Are the Main Side Effects of Cagrilintide?

Gastrointestinal effects dominate, especially nausea, vomiting, and reduced appetite, similar to GLP-1 drugs. They are usually mild to moderate and managed by gradually escalating the dose over several weeks.

Can I Buy Cagrilintide Now?

Not as an approved medication. Cagrilintide is still investigational, so it cannot be legitimately prescribed yet. Versions sold online as research peptides are unapproved and carry real risks around purity, dosing, and safety with no medical oversight.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.